Article and Video CATEGORIES
Assistant Professor of Medicine, Hospital of the University of Pennsylvania, and the Veteran’s Administration Medical Center
We are pleased to present this newest video series of updates from ASCO and ESMO 2020, with discussions on updates to head and neck cancer treatments and trials.
Dr. Joshua Bauml, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and Dr. Jared Weiss, Associate Professor of Medicine at UNC Chapel Hill and Vice President of the Board of GRACE chaired this program highlighting updates for those dealing with a diagnosis of locally advanced HNSCC. Drs. Bauml and Weiss spoke with Dr. Kathryn Gold, Medical Oncologist and Associate Professor of Medicine at the University of California San Diego and Dr. Ranee Mehra, Professor of Medical Oncology at the University of Maryland, on the newest updates to 2020 trials and studies presented at ASCO and ESMO this year.
For this discussion, Drs. Bauml, Weiss, Gold and Mehra discuss the outcome of the PembroRAD Trial: Pembrolizumab (Keytruda) or Cetuximab (Erbitux) combined with radiation therapy in patients with locally advanced HNSCC.
To join the conversation, visit https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…
That's beautiful Linda. Thank you,